142 related articles for article (PubMed ID: 23020673)
21. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
Georgakis GV; Li Y; Younes A
Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
[TBL] [Abstract][Full Text] [Related]
22. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
23. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.
Kawamata N; Chen J; Koeffler HP
Blood; 2007 Oct; 110(7):2667-73. PubMed ID: 17606765
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
25. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
[TBL] [Abstract][Full Text] [Related]
26. Iron chelation in the treatment of cancer: a new role for deferasirox?
Bedford MR; Ford SJ; Horniblow RD; Iqbal TH; Tselepis C
J Clin Pharmacol; 2013 Sep; 53(9):885-91. PubMed ID: 23740857
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
28. Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
Loza-Rosas SA; Vázquez-Salgado AM; Rivero KI; Negrón LJ; Delgado Y; Benjamín-Rivera JA; Vázquez-Maldonado AL; Parks TB; Munet-Colón C; Tinoco AD
Inorg Chem; 2017 Jul; 56(14):7788-7802. PubMed ID: 28644630
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
[TBL] [Abstract][Full Text] [Related]
30. Iron chelators induce autophagic cell death in multiple myeloma cells.
Pullarkat V; Meng Z; Donohue C; Yamamoto VN; Tomassetti S; Bhatia R; Krishnan A; Forman SJ; Synold TW
Leuk Res; 2014 Aug; 38(8):988-96. PubMed ID: 24998390
[TBL] [Abstract][Full Text] [Related]
31. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
32. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
[TBL] [Abstract][Full Text] [Related]
33. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
Chen R; Chubb S; Cheng T; Hawtin RE; Gandhi V; Plunkett W
Cancer Res; 2010 Aug; 70(16):6587-97. PubMed ID: 20663900
[TBL] [Abstract][Full Text] [Related]
34. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
[TBL] [Abstract][Full Text] [Related]
35. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
[No Abstract] [Full Text] [Related]
36. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Lescoat G; Chantrel-Groussard K; Pasdeloup N; Nick H; Brissot P; Gaboriau F
Cell Prolif; 2007 Oct; 40(5):755-67. PubMed ID: 17877614
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
Bogner C; Ringshausen I; Schneller F; Fend F; Quintanilla-Martinez L; Häcker G; Goetze K; Oostendorp R; Peschel C; Decker T
Br J Haematol; 2003 Jul; 122(2):260-8. PubMed ID: 12846895
[TBL] [Abstract][Full Text] [Related]
38. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.
Klier M; Anastasov N; Hermann A; Meindl T; Angermeier D; Raffeld M; Fend F; Quintanilla-Martinez L
Leukemia; 2008 Nov; 22(11):2097-105. PubMed ID: 18685613
[TBL] [Abstract][Full Text] [Related]
39. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
